Due to its poor specificity, total PSA quantification is often associated with the risk of overdiagnosis [155, 162] which leads to overtreatment and the associated side effects such as sexual dysfunction, urinary incontinence, bowel problems, together with increased healthcare costs [163]. The gene discussed is KLK3; the disease is sexual dysfunction.